UK Biomedical Cluster, Pfizer Partner to Translate Basic Science into Rare Disease Treatments | GenomeWeb

NEW YORK (GenomeWeb) – The Global Medical Excellence Cluster (GMEC), a UK non-profit focused on advancing translational research, has inked an agreement with Pfizer to use molecular and genomic technologies to develop medicines for treating rare diseases.

Under the five-year initiative, investigators at GMEC's partnering universities will work with Pfizer scientists in joint programs aiming to translate basic research into new drugs for treating rare diseases, GMEC said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.